Clinical Trial Update: Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial uses Norton-Simon model-based dosing to evaluate biweekly capecitabine with bevacizumab for metastatic breast cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-01-22